Dorothy Puhy Biography and Net Worth

Director of Abiomed

Dorothy was elected to the Blue Cross Blue Shield of Massachusetts Board in 2012, was elected chair in 2020. She served as vice chair from 2017 to 2019. As a director, she helps set the company’s strategy and overall direction. Within a highly competitive and highly regulated business environment, the board oversees and governs BCBSMA's operations, which includes the provision of health coverage to individuals and public and private employers. Dorothy serves as a member of the finance and business performance committee and the governance committee.

Dorothy previously served as executive vice president and chief operating officer for the Dana-Farber Cancer Institute until her retirement on March 1. 2019. Starting in 1994, she served as chief financial officer of Dana-Farber. She was on the adjunct faculty at Harvard School of Public Health for many years.

Dorothy is a director, chair of the Financial Committee and member of the audit, governance and investment committees at CRICO (Controlled Risk Insurance Company), the Harvard medical malpractice captive. She is lead director and chair of the audit committee at Abiomed Inc. At Eaton Vance Corp. she is a director, chair of the nominating and governance committees and member of its audit committee.

Dorothy earned her Master of Business Administration from the Wharton School and received a Bachelor of Arts degree from the University of Pennsylvania.

What is Dorothy E. Puhy's net worth?: The estimated net worth of Dorothy E. Puhy is at least $2.92 million as of July 15th, 2020. Ms. Puhy owns 7,652 shares of Abiomed stock worth more than $2,915,565 as of April 19th. This net worth estimate does not reflect any other assets that Ms. Puhy may own. Learn More about Dorothy E. Puhy's net worth.
How do I contact Dorothy E. Puhy?: The corporate mailing address for Ms. Puhy and other Abiomed executives is 22 CHERRY HILL DR, DANVERS MA, 01923. Abiomed can also be reached via phone at (978) 646-1400 and via email at [email protected]. Learn More on Dorothy E. Puhy's contact information.
Has Dorothy E. Puhy been buying or selling shares of Abiomed?: Dorothy E. Puhy has not been actively trading shares of Abiomed during the last quarter. Most recently, Dorothy E. Puhy sold 7,500 shares of the business's stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $275.00, for a transaction totalling $2,062,500.00. Following the completion of the sale, the director now directly owns 7,652 shares of the company's stock, valued at $2,104,300. Learn More on Dorothy E. Puhy's trading history.
Who are Abiomed's active insiders?: Abiomed's insider roster includes Marc Began (VP), Andrew Greenfield (VP), Michael Minogue (CEO), Michael Minogue (CEO), Dorothy Puhy (Director), Joseph Riccelli, Sr. (CEO), Martin Sutter (Director), Paul Thomas (Director), Todd Trapp (CFO), David Weber (COO), and Magdalena Yesil (Director). Learn More on Abiomed's active insiders.

Dorothy E. Puhy Insider Trading History at Abiomed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/15/2020	Sell	7,500	$275.00	$2,062,500.00	7,652
10/30/2017	Sell	6,364	$179.08	$1,139,665.12	39,532
5/8/2017	Sell	13,500	$131.12	$1,770,120.00	38,249
12/13/2016	Sell	8,000	$120.00	$960,000.00	32,749
8/15/2016	Sell	5,160	$123.94	$639,530.40	24,749
8/10/2016	Sell	3,900	$122.31	$477,009.00	33,811
4/1/2016	Sell	10,000	$95.02	$950,200.00	47,792
3/22/2016	Sell	10,000	$90.30	$903,000.00	52,190
3/7/2016	Sell	4,000	$85.00	$340,000.00	66,190
2/8/2016	Sell	4,000	$80.47	$321,880.00	62,190
8/17/2015	Sell	2,580	$103.91	$268,087.80
8/14/2015	Sell	2,580	$105.27	$271,596.60

Dorothy E. Puhy Buying and Selling Activity at Abiomed

Abiomed Company Overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Today's Range

Now: $381.02

$381.02

50 Day Range

MA: $380.55

$377.20

$381.30

2 Week Range

Now: $381.02

$219.85

$381.99

Volume

258 shs

Average Volume

611,028 shs

Market Capitalization

$17.18 billion

P/E Ratio

65.47

Dividend Yield

N/A

Beta

1.4

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…